Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
Roivant Sciences Ltd. (ROIV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Platinum Asset Management Kerr Neilson | 481,335 | $5,424,645 | -3% | 0.36% |
| 2. | Cutter Capital Vince Aita | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.00 | 4,000,000 | $20,000,000.00 | 102,849,443 | 2022-11-10 | Filing | |
| $3.91 | 8,600 | $33,635.46 | 98,849,443 | 2022-04-25 | Filing | |
| $3.83 | 31,685 | $121,318.70 | 98,840,843 | 2022-04-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.52 | 100,000 | $1,152,000.00 | 1,462,223 | 2025-07-21 | Filing | |
| $11.45 | 100,000 | $1,145,000.00 | 1,462,223 | 2025-06-20 | Filing | |
| $11.46 | 577,007 | $6,612,500.22 | 37,284,108 | 2025-06-20 | Filing | |
| $11.45 | 565,266 | $6,472,295.70 | 37,861,115 | 2025-06-18 | Filing | |
| $11.19 | 200,800 | $2,246,952.00 | 38,426,381 | 2025-06-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,691,632 | $19,064,693 | 2.15% | |
| 2. | 406,859 | $4,583,266 | 0% | |
| 3. | 209,363 | $2,359,521 | 0.03% | |
| 4. | 162,400 | $1,830,248 | 0% | |
| 5. | 155,000 | $1,746,850 | 0.15% |
News See All
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Roivant Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Why Roivant Sciences Ltd. (ROIV) Surged On Thursday
We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a look at where Roivant Sciences Ltd.
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
The reiteration comes after the company appointed the current President and COO of Roivant, Dr. Eric Venker as CEO of Immunovant. Roivant Sciences Ltd.
Billionaire David Einhorn's 10 Stock Picks with Huge Upside Potential
David Einhorn is a widely renowned hedge fund manager who co-founded Greenlight Capital in 1996.
Billionaire Andreas Halvorsen's 10 Stock Picks With Huge Upside Potential
Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson's Tiger Management.
Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn
Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession.
Billionaire Hedge Funds
